ENX-105

ENX-105 is an investigational small-molecule psychotropic designed as a deuterated single-enantiomer derivative of nemonapride, developed by Engrail Therapeutics for neuropsychiatric indications, notably post-traumatic stress disorder and mood disorders. It acts as a high-affinity dopamine D2/D3 receptor antagonist and a serotonin 5-HT1A and 5-HT2A receptor agonist, with subnanomolar to low-nanomolar potency reported at D2/D3 and low-nanomolar EC50s at 5-HT2A and 5-HT1A. In rodent studies, it showed anxiolytic-, antipsychotic-, anti-anhedonic-, and pro-cognitive-like effects and increased nucleus accumbens dopamine without eliciting head-twitch behavior, suggesting non-hallucinogenic 5-HT2A agonism. Development was at the preclinical stage and, per a 2025 pipeline update, was discontinued in the USA for PTSD and mood disorders. [Wikipedia reports formula C21H21ClD5N3O2; molar mass 392.94 g/mol.] [Mechanistic and preclinical details reflect Engrail’s platform lineage alongside ENX-104.]

Other names

Deuterated nemonapride enantiomer